Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The RX renal instruction is explicitly indexed and excludes hemodialysis from the stated severe-renal regimen.
Before applying: Do not silently relabel the metric or extend the nondialysis regimen to dialysis. Review other myopathy and interaction risks.
Also check: Preserve indexed creatinine-clearance units and the nondialysis qualification
Rxlist source
GlobalRPh RX List - CRESTOR
Product / population
Rosuvastatin - CRESTOR tablets; selected renal passages, not a complete prescribing monograph.
Renal measure
Creatinine clearance printed as CLcr in mL/min/1.73 m2; indexed, not silently converted to unindexed CrCl or eGFR.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
Limits that apply to these rows
Renal impairment increases myopathy/rhabdomyolysis risk. Keep indexed units and the non-hemodialysis qualification. No HD dose is inferred.
Rosuvastatin - renal guidance
Indexed CLcr, mL/min/1.73 m2
Source-specific dose / instruction
<30, not receiving hemodialysis
Start 5 mg once daily; maximum 10 mg/day
Mild/moderate impairment
No specific renal adjustment in this source
Read the retained text before reformatting
For severe impairment with indexed CLcr <30 mL/min/1.73 m2 in a patient not receiving hemodialysis, start 5 mg once daily and do not exceed 10 mg/day. Mild/moderate impairment does not require a specific renal adjustment in this source. Renal impairment increases myopathy/rhabdomyolysis risk. Preserve the source's indexed creatinine-clearance units and nondialysis qualification rather than substituting an unindexed cutoff or extending this regimen to hemodialysis.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
scope and safety
Preserve indexed creatinine-clearance units and the nondialysis qualification
The RX renal instruction is explicitly indexed and excludes hemodialysis from the stated severe-renal regimen.
How to use this: Do not silently relabel the metric or extend the nondialysis regimen to dialysis. Review other myopathy and interaction risks.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - CRESTOR
Rosuvastatin - CRESTOR tablets; selected renal passages, not a complete prescribing monograph.
Method: Creatinine clearance printed as CLcr in mL/min/1.73 m2; indexed, not silently converted to unindexed CrCl or eGFR.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content
Original GlobalRPh protocol
Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/rosuvastatin/
Usual Dosing (Adults)
Usual start 10 mg once daily (initial range 5-20 mg). Reserve higher initial doses for severe hypercholesterolemia or homozygous familial hypercholesterolemia. Titrate after 2 weeks in 5-10 mg daily increments. Range 5-40 mg/day; maximum 40 mg daily.
GRPH-rosuvastatin-01 · Source section: Usual Dosing (Adults)Renal section finder
Renal Dosing
Limits that apply to these rows
Original source leaves exactly 30 unassigned. Hemodialysis data are insufficient; do not transfer this non-HD regimen.
Historical rosuvastatin renal instruction
Indexed units, mL/min/1.73 m2
Source-specific dose / instruction
>30
No change in this source
<30 and not on HD
Start 5 mg daily; do not exceed 10 mg daily
Read the retained text before reformatting
The source uses indexed units mL/min/1.73 m2: above 30, no change; below 30 and not on HD, start 5 mg daily and do not exceed 10 mg daily. Exactly 30 is not explicitly assigned.
GlobalRPh-hosted RX List · Rosuvastatin - CRESTOR tablets; selected renal passages, not a complete prescribing monograph.
Renal method: Creatinine clearance printed as CLcr in mL/min/1.73 m2; indexed, not silently converted to unindexed CrCl or eGFR. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Limits that apply to these rows
Renal impairment increases myopathy/rhabdomyolysis risk. Keep indexed units and the non-hemodialysis qualification. No HD dose is inferred.
Rosuvastatin - renal guidance
Indexed CLcr, mL/min/1.73 m2
Source-specific dose / instruction
<30, not receiving hemodialysis
Start 5 mg once daily; maximum 10 mg/day
Mild/moderate impairment
No specific renal adjustment in this source
Read the retained text before reformatting
For severe impairment with indexed CLcr <30 mL/min/1.73 m2 in a patient not receiving hemodialysis, start 5 mg once daily and do not exceed 10 mg/day. Mild/moderate impairment does not require a specific renal adjustment in this source. Renal impairment increases myopathy/rhabdomyolysis risk. Preserve the source's indexed creatinine-clearance units and nondialysis qualification rather than substituting an unindexed cutoff or extending this regimen to hemodialysis.
RDM52-rxlist-rosuvastatin-c2269d8a9f-C1 · Source locator: Dosage in severe renal impairment; renal population and myopathy risk.
Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.